Navigation Links
Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009

POINT RICHMOND, Calif., May 28 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to present at the 8th Annual Needham Life Science Conference in New York City on Wednesday, June 10, 2009 at 3:00 p.m., Eastern Time.

An audio webcast of the presentation will be available at The audio replay of the presentation will be available at the same location through July 10, 2009.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. On January 30, 2009, Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to "Transcept Pharmaceuticals, Inc." and its NASDAQ ticker symbol to "TSPT." The combined company resources resulting from the merger are expected to enable Transcept to carry out its plans to commercialize its lead product candidate, Intermezzo(R). If approved on the timing anticipated, Intermezzo(R) is expected to be the first commercially available sleep aid designed specifically for use in the middle of the night when patients awaken and have difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted a New Drug Application (NDA) for Intermezzo(R) to the U.S. Food and Drug Administration (FDA), which was accepted for filing on December 15, 2008. The FDA has assigned a PDUFA date of July 30, 2009 to the Intermezzo(R) NDA.

For further information, please visit the company's website at:

Forward Looking Statements

This press release contains forward looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the ability of merger proceeds to be sufficient to carry out its plans to commercialize Intermezzo(R); and the potential for Intermezzo(R) to receive timely FDA approval and be the first commercially available sleep aid specifically designed for use in the middle of the night. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, delays in FDA approval of Intermezzo(R); unanticipated additional expenses in connection with the commercialization of Intermezzo(R), if approved; Transcept product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of Transcept product candidates.

    Transcept Pharmaceuticals, Inc.         The Ruth Group
    Michael Gill                            Investors / Media
    Director of Communications              Stephanie Carrington / Jason Rando
    (510) 215-3575                          (646) 536-7017 / 7025           

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
2. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
3. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
4. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
5. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
6. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
7. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
8. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
9. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
10. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
(Date:11/24/2015)... Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... it deems a growing epidemic as deaths from prescription opioids in the United States ... heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of all ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a holistic treatment ... video interviews with some of the staff members at their recovery center. The videos ... as well as some of the things that make their recovery program so unique. ...
(Date:11/24/2015)... PALMYRA, Wis (PRWEB) , ... November 24, 2015 ... ... Process scholarship award at Cleveland University-Kansas City (CU-KC), in Overland Park, ... scholarship from Chiropractor and University President Carl S. Cleveland III on October 16. ...
(Date:11/24/2015)... N.Y. (PRWEB) , ... November 24, 2015 , ... Autism ... Tuesday, the global movement driven by social media and the generosity of people around ... then encourage their social media networks to give – and share the personal stories ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of patented products, announces Fragrance by Marcelle, a cosmetic invention which offers a ... & Fragrance Manufacturing Market in the US is worth $3 billion annually," says ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015 Avery Biomedical Devices (ABD), manufacturer ... announce the appointment of Anders Jonzon , MD; ... Dr. Jonzon is a Physiologist ... Hospital, Uppsala University, Uppsala and Children,s Hospital, Karolinska, ... a fellow at the Cardiovascular Institute (UCSF). His research ...
(Date:11/24/2015)... 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... of Directors has declared a special 1 percent stock dividend ... payable December 14, 2015, to shareholders of record December 7, ... additional shares of common stock. --> ... a strong endorsement of our confidence in Ascendant,s growth strategy ...
(Date:11/24/2015)... st  Scientific Assembly and Annual Meeting of the Radiological Society ... Chicago on Nov-29 th through Dec-4 ...  Scientific Assembly and Annual Meeting of the Radiological Society of ... Chicago on Nov-29 th through Dec-4 th , ... present its revolutionary whole body CZT digital SPECT/CT solution at the ...
Breaking Medicine Technology: